Fibrosis in chronic liver diseases: Diagnosis and management

Journal of Hepatology

Volumn 42, Issue SUPPL. 1, 2005, Pages

  Pinzani, Massimo ^a   Rombouts, Krista ^a   Colagrande, Stefano ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 GLOBULIN; ALPHA 2 MACROGLOBULIN; ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; APOLIPOPROTEIN A1; BILIRUBIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 6; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; IMMUNOGLOBULIN; TENASCIN;

ALCOHOL CONSUMPTION; BILIRUBIN BLOOD LEVEL; CHRONIC DISEASE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CYTOPATHOLOGY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; EXTRACELLULAR MATRIX; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW;

EID: 14944343292     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.12.008     Document Type: Review

References (156)

1. S.L. Friedman Liver fibrosis - from bench to bedside J Hepatol 38 2003 S38 S53
2. V.J. Desmet, and T. Roskams Cirrhosis reversal: a duel between dogma and myth J Hepatol 40 2004 860 867
3. H.B. El-Serag Hepatocellular carcinoma and hepatitis C in the United States Hepatology 36 2002 S74 S83
4. A.S. Befeler, and A.M. Di Bisceglie Hepatocellular carcinoma: diagnosis and treatment Gastroenterology 122 2002 1609 1619
5. M.L. Shiffman, R.T. Stravitz, M.J. Contos, A.S. Mills, R.K. Sterling, and V.A. Luketic Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation Liver Transpl 10 2004 1248 1255
6. Y. Benhamou, M. Bochet, V. Di Martino, F. Charlotte, F. Azria, and A. Coutellier Liver fibrosis progression in human immunodeficiency virus and hepatitis C coinfected patients Hepatology 30 1999 1054 1058
7. K. Safdar, and E.R. Schiff Alcohol and hepatitis C Semin Liver Dis 24 2004 305 315
8. S.D. Ryder, W.L. Irving, D.A. Jones, K.R. Neal, J.C. Underwood, and Trent Hepatitis C Study Group Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study Gut 53 2004 451 455
9. D. Cassiman, and T. Roskams Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cell research J Hepatol 37 2002 527 535
10. M. Pinzani, and K. Rombouts Liver fibrosis: from the bench to clinical targets Dig Liver Dis 36 2004 231 242
11. T. Poynard, M.F. Yuen, V. Ratziu, and C.L. Lai Viral hepatitis C Lancet 362 2003 2095 2100
12. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825 832
13. M. Pinzani, R.G. Romanelli, and S. Magli Progression of fibrosis in chronic liver diseases: time to tally the score J Hepatol 34 2001 764 767
14. T. Poynard, P. Mathurin, C.L. Lai, D. Guyader, R. Poupon, and M.H. Tainturier A comparison of fibrosis progression in chronic liver diseases J Hepatol 38 2003 257 265
15. A. Regev, M. Berho, L.J. Jeffers, C. Milikowski, E.G. Molina, and N.T. Pyrsopoulos Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection Am J Gastroenterol 97 2002 2614 2618
16. P. Bedossa, D. Dargere, and V. Paradis Sampling variability of liver fibrosis in chronic hepatitis C Hepatology 38 2003 1449 1457
17. G. Colloredo, M. Guido, A. Sonzogni, and G. Leandro Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease J Hepatol 39 2003 239 244
18. E. Brunetti, E. Silini, A. Pistorio, A. Cavallero, A. Marangio, and R. Bruno Coarse vs. fine needle aspiration biopsy for the assessment of diffuse liver disease from hepatitis C virus-related chronic hepatitis J Hepatol 40 2004 501 506
19. M. Guido, and M. Rugge Liver biopsy sampling in chronic viral hepatitis Semin Liver Dis 24 2004 89 97
20. L.C. Junqueira, W. Cossermelli, and R. Brentani Differential staining of collagens type I, II and III by Sirius Red and polarization microscopy Arch Histol Jpn 41 1978 267 274
21. H. Puchtler, and F.W. Waldrop Silver impregnation methods for reticulum fibers and reticulin: a re-investigation of their origins and specificity Histochemistry 57 1978 177 187
22. R. Marcos, R.A. Monteiro, and E. Rocha Estimation of the number of stellate cells in a liver with the smooth fractionator J Microsc 215 2004 174 182
23. V. Paradis, D. Dargere, M. Vidaud, A.C. De Gouville, S. Huet, and V. Martinez Expression of connective tissue growth factor in experimental rat and human liver fibrosis Hepatology 30 1999 968 976
24. V. Paradis, G. Perlemutter, F. Bonvoust, D. Dargere, B. Parfait, and M. Vidaud High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression of fibrosis in nonalcoholic steatohepatitis Hepatology 34 2001 738 744
25. A.W. Rachfal, and D.R. Brigstock Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis Hepatol Res 26 2003 1 9
26. P. Bedossa, T. Poynard, P. Mathurin, G. Lemaigre, and J.C. Chaput Transforming growth factor Beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon Gut 34 1993 S146 S147
27. S. Kanzler, M. Baumann, P. Schirmacher, V. Dries, E. Bayer, and G. Gerken Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta J Viral Hepat 8 2001 430 437
28. M. Pinzani, S. Milani, H. Herbst, R. De Franco, C. Grappone, and A. Gentilini Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis Am J Pathol 148 1996 785 800
29. E.M. Brunt Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond Hepatology 31 2000 241 246
30. N.H. Afdhal, and D. Nunes Evaluation of liver fibrosis: a concise review Am J Gastroenterol 99 2004 1160 1174
31. T. Poynard, A. Aubert, P. Bedossa, A. Abella, S. Naveau, and F. Paraf A simple biological index for detection of alcoholic liver disease in drinkers Gastroenterology 100 1991 1397 1402
32. S. Naveau, T. Poynard, C. Benattat, P. Bedossa, and J.C. Chaput Alpha-2 macroglobulin and hepatic fibrosis:diagnostic interest Dig Dis Sci 11 1994 2426 2432
33. F. Imbert-Bismut, V. Ratziu, L. Pieroni, F. Charlotte, Y. Benhamou, T. Poynard, and MULTIVIRC Group Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study Lancet 357 2001 1069 1075
34. R.P. Myers, Y. Benhamou, F. Imbert-Bismut, V. Thibault, M. Bochet, and F. Charlotte Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients AIDS 17 2003 721 725
35. E. Rossi, L. Adams, A. Prins, M. Bulsara, B. de Boer, and G. Garas Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients Clin Chem 4 2003 450 454
36. X. Forns, S. Ampurdanes, J.M. Llovet, J. Aponte, L. Quinto, and E. Martinez-Bauer Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model Hepatology 36 2002 986 992
37. C.T. Wai, J.K. Greenson, R.J. Fontana, J.D. Kalbfleisch, J.A. Marrero, and H.S. Conjeevaram A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatits C Hepatology 38 2003 518 526
38. M. Yamauchi, Y. Mizuhara, Y. Maezawa, and G. Toda Serum tenascin levels in chronic liver disease Liver 14 1994 148 153
39. J.G. McHutchison, L.M. Blatt, M. de Medina, J.R. Craig, A. Conrad, and E.R. Schiff Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group J Gastroenterol Hepatol 15 2000 945 951
40. A. Hayasaka, D. Schuppan, K. Ohnishi, K. Okuda, and E.G. Hahn Serum concentrations of the carboxyterminal cross-linking domain of procollagen type IV (NC1) and the aminoterminal propeptide of procollagen type III (PIIIP) in chronic liver disease J Hepatol 10 1990 17 22
41. D. Schuppan, M.C. Cantaluppi, J. Becker, A. Veit, T. Bunte, and D. Troyer Undulin, an extracellular matrix glycoprotein associated with collagen fibrils J Biol Chem 265 1990 8823 8832
42. Y. Murawaki, Y. Ikuta, M. Koda, and H. Kawasaki Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology Hepatology 20 1994 780 787
43. A. Kasahara, N. Hayashi, K. Mochizuki, M. Oshita, K. Katayama, and M. Kato Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response J Hepatol 26 1997 574 583
44. Y. Murawaki, Y. Ikuta, K. Okamoto, M. Koda, and H. Kawasaki Serum matrix metalloproteinase-3 (stromelysin-1) concentration in patients with chronic liver disease J Hepatol 31 1999 474 481
45. J.C. Trinchet Clinical use of serum markers of fibrosis in chronic hepatitis J Hepatol 22 1995 89 95
46. L. Castera, D.J. Hartmann, F. Chapel, C. Guettier, F. Mall, and T. Lons Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis J Hepatol 32 2000 412 418
47. C. Pilette, M.C. Rousselet, P. Bedossa, D. Chappard, F. Oberti, and H. Rifflet Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers J Hepatol 28 1998 439 446
48. J. Guechot, A. Laudat, A. Loria, L. Serfaty, R. Poupon, and J. Giboudeau Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis Clin Chem 42 1996 558 563
49. Y. Murawaki, Y. Ikuta, M. Koda, Y. Nishimura, and H. Kawasaki Clinical significance of serum hyaluronan in patients with chronic viral liver disease J Gastroenterol Hepatol 11 1996 459 465
50. J.S. Johansen, P. Christoffersen, S. Moller, P.A. Price, J.H. Henriksen, and C. Garbarsch Serum YKL-40 is increased in patients with hepatic fibrosis J Hepatol 32 2000 911 920
51. C. Nojgaard, J.S. Johansen, H.B. Krarup, M. Holten-Andersen, A. Moller, F. Bendtsen, and Danish Viral Hepatitis Study Group Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C Scandinavian J Gastroenterol 38 2003 659 665
52. K. Patel, A. Lajoie, S. Heaton, S. Pianko, C.A. Behling, and D. Bylund Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C J Gastroenterol Hepatol 18 2003 253 257
53. W.M.C. Rosenberg, M. Voelker, M. Becka, A. Burt, D. Schuppan, and S. Hubcher A cohort study of a panel of serum markers as predictors of hepatic fibrosis as assessed with liver histology and image analysis Gastroenterology 127 2004 1704 1713
54. S. Gaiani, L. Gramantieri, N. Venturoli, F. Piscaglia, S. Siringo, and A. D'Errico What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy J Hepatol 27 1997 979 985
55. C. Aube, F. Oberti, N. Korali, M.A. Namour, D. Loisel, and J.Y. Tanguy Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis J Hepatol 30 1999 472 478
56. A. Colli, M. Fraquelli, M. Andreoletti, B. Marino, E. Zuccoli, and D. Conte Severe liver fibrosis or cirrhosis: accuracy of US for detection - analysis of 300 cases Radiology 227 2003 89 94
57. F. Oberti, E. Valsesia, C. Pilette, M.C. Rousselet, P. Bedossa, and C. Aube Noninvasive diagnosis of hepatic fibrosis or cirrhosis Gastroenterology 113 1997 1609 1616
58. C. Aube, B. Winkfield, F. Oberti, E. Vuillemin, M.C. Rousselet, and C. Caron New Doppler ultrasound signs improve the non-invasive diagnosis of cirrhosis or severe liver fibrosis Eur J Gastroenterol Hepatol 16 2004 743 751
59. L. Annet, R. Materne, E. Danse, J. Jamart, Y. Horsmans, and B.E. Van Beers Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension Radiology 229 2003 409 414
60. M. Pinzani, and P. Gentilini Biology of the hepatic stellate cells and its possible relevance in the pathogenesis of portal hypertension in cirrhosis Semin Liver Dis 19 1999 397 410
61. A. Hoofring, J. Boitnott, and M. Torbenson Three-dimensional reconstruction of hepatic bridging fibrosis in chronic hepatitis C viral infection J Hepatol 39 2003 738 741
62. W.P. Chen, J.H. Chen, J.I. Hwang, J.W. Tsai, J.S. Chen, and S.W. Hung Spectrum of transient hepatic attenuation differences in biphasic helical CT Am J Radiol 172 1999 419 424
63. Y. Itai, and O. Matsui Blood flow and liver imaging Radiology 202 1997 306 314
64. S. Colagrande, L. Carmignani, A. Pagliari, L. Capaccioli, and N. Villari Portal trunk thrombosis, decreased portal inflow and effect on hepatic blood supply. About two cases studied with helical CT Radiol Med 99 2000 103 106
65. S. Colagrande, N. Centi, G. La Villa, and N. Villari Transient hepatic attenuation differences Am J Roentgenol 183 2004 459 464
66. R. Materne, A.M. Smith, F. Peeters, J.P. Dehoux, A. Keyeux, and Y. Horsmans Assessment of hepatic perfusion parameters with dynamic MRI Magn Reson Med 47 2002 135 142
67. K.A. Miles, M.R. Griffiths, and C.T.:. Perfusion Perfusion CT: a worthwhile enhancement? Br J Radiol 76 2003 220 231
68. B.E. Van Beers, R. Materne, L. Annet, L. Hermoye, C. Sempoux, and F. Peeters Capillarization of the sinusoids in liver fibrosis: noninvasive assessment with contrast-enhanced MRI in the rabbit Magn Reson Med 49 2003 692 699
69. B. Taouli, V. Vilgrain, E. Dumont, J.L. Daire, B. Fan, and Y. Menu Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients Radiology 226 2003 71 78
70. A.K. Burroughs, R. Groszmann, J. Bosch, N. Grace, G. Garcia-Tsao, and D. Patch Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 50 2002 425 427
71. M. Ziol, A. Handra-Luca, A. Kettaneh, C. Christidis, F. Mal, F. Kazemi, and V. de Ledinghen Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C Hepatology 41 2004 48 54
72. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI and Liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; in press.
73. R. Bataller, K.E. North, and D.A. Brenner Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal Hepatology 37 2003 493 503
74. M.W. Smith, Z.N. Yue, M.J. Korth, H.A. Do, L. Boix, and N. Fausto Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers Hepatology 38 2003 1458 1467
75. M.J. Bahr, M. el Menuawy, K.H. Boeker, P.B. Musholt, M.P. Manns, and R. Lichtinghagen Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C Liver Int 23 2003 420 425
76. J.B. Dixon, P.S. Bhathal, J.R. Jonsson, A.F. Dixon, E.E. Powell, and P.E. O'Brien Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese J Hepatol 39 2003 967 971
77. M. Muhlbauer, A.K. Bosserhoff, A. Hartmann, W.E. Thasler, T.S. Weiss, and H. Herfarth A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease Gastroenterology 125 2003 1085 1093
78. M. Wright, R. Goldin, S. Hellier, S. Knapp, A. Frodsham, and B. Hennig Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection Gut 52 2003 1206 1210
79. M. Romero-Gomez, M.A. Montes-Cano, M.A. Otero-Fernandez, B. Torres, and D. Sanchez-Munoz SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C Gut 53 2004 446 450
80. S.L. Friedman Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury J Biol Chem 275 2000 2247 2250
81. S.J. Lee, Y.G. Kim, K.W. Kang, C.W. Kim, and S.G. Kim Effects of colchicine on liver functions of cirrhotic rats: beneficial effects result from stellate cell inactivation and inhibition of TGF beta1 expression Chem Biol Interact 147 2004 9 21
82. R.E. Poupon, P.M. Huet, R. Poupon, A.M. Bonnand, J.T. Nhieu, and E.S. Zafrani A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group Hepatology 24 1996 1098 1103
83. A.Y. Hui, A.J. Dannenberg, J.J. Sung, K. Subbaramaiah, B. Du, and P. Olinga Prostaglandin E2 inhibits transforming growth factor beta 1-mediated induction of collagen alpha 1(I) in hepatic stellate cells J Hepatol 41 2004 251 258
84. E. Shimizu, Y. Kobayashi, Y. Oki, T. Kawasaki, T. Yoshimi, and H. Nakamura OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells Life Sci 64 1999 2081 2088
85. S. Fiorucci, E. Antonelli, G. Rizzo, B. Renga, A. Mencarelli, and L. Riccardi The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis Gastroenterology 127 2004 1497 1512
86. R.G. Romanelli, A. Caligiuri, V. Carloni, R. DeFranco, P. Montalto, and E. Ceni Effect of pentoxifylline on the degradation of procollagen type I produced by human hepatic stellate cells in response to transforming growth factor-β1 Br J Pharmacol 122 1997 1047 1054
87. C. Raetsch, J.D. Jia, G. Boigk, M. Bauer, E.G. Hahn, and E.O. Riecken Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis Gut 50 2002 241 247
88. T. Niki, K. Rombouts, P. De Bleser, K. De Smet, V. Rogiers, and D. Schuppan A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture Hepatology 29 1999 858 867
89. K. Hellemans, I. Grinko, K. Rombouts, D. Schuppan, and A. Geerts All-trans and 9-cis retinoic acid alter rat hepatic stellate cell phenotype differentially Gut 45 1999 134 142
90. K. Rombouts, E. Kisanga, K. Hellemans, A. Wielant, D. Schuppan, and A. Geerts Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells J Hepatol 38 2003 564 572
91. A. Caligiuri, R.M. De Franco, R.G. Romanelli, A. Gentilini, M. Meucci, and P. Failli Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells Gastroenterology 124 2003 504 520
92. Y.Z. Zhao, J.Y. Kim, E.J. Park, S.H. Lee, S.W. Woo, and G. Ko Tetrandrine induces apoptosis in hepatic stellate cells Phytother Res 18 2004 306 309
93. S.W. Woo, S.H. Lee, H.C. Kang, E.J. Park, Y.Z. Zhao, and Y.C. Kim Butein suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture J Pharm Pharmacol 55 2003 347 352
94. H. Ikeda, S. Nagoshi, A. Ohno, M. Yanase, H. Maekawa, and K. Fujiwara Activated rat stellate cells express c-met and respond to hepatocyte growth factor to enhance transforming growth factor beta1 expression and DNA synthesis Biochem Biophys Res Commun 250 1998 769 775
95. T. Ueki, Y. Kaneda, H. Tsutsui, K. Nakanishi, Y. Sawa, and R. Morishita Hepatocyte growth factor gene therapy of liver cirrhosis in rats Nat Med 5 1999 226 230
96. R. Bruck, O. Genina, H. Aeed, R. Alexiev, A. Nagler, and Y. Avni Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats Hepatology 33 2001 379 386
97. L.J. Zhang, Y.X. Chen, Z.X. Chen, Y.H. Huang, J.P. Yu, and X.Z. Wang Effect of interleukin-10 and platelet-derived growth factor on expressions of matrix metalloproteinases-2 and tissue inhibitor of metalloproteinases-1 in rat fibrotic liver and cultured hepatic stellate cells World J Gastroenterol 10 2004 2574 2579
98. S.C. Wang, M. Ohata, L. Schrum, R.A. Rippe, and H. Tsukamoto Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells J Biol Chem 273 1998 302 308
99. Q. Cao, K.M. Mak, and C.S. Lieber DLPC decreases TGF-beta1-induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells Am J Physiol Gastrointest Liver Physiol 283 2002 G1051 G1061
100. R.G. Bennett, K.K. Kharbanda, and D.J. Tuma Inhibition of markers of hepatic stellate cell activation by the hormone relaxin Biochem Pharmacol 66 2003 867 874
101. M. Okuno, K. Akita, H. Moriwaki, N. Kawada, K. Ikeda, and K. Kaneda Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta Gastroenterology 120 2001 1784 1800
102. M. Aoyagi, I. Sakaida, C. Suzuki, M. Segawa, Y. Fukumoto, and K. Okita Prolyl 4-hydroxylase inhibitor is more effective for the inhibition of proliferation than for inhibition of collagen synthesis of rat hepatic stellate cells Hepatol Res 23 2002 1 6
103. M. Bickel, K.H. Baringhaus, M. Gerl, V. Gunzler, J. Kanta, and L. Schmidts Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor Hepatology 28 1998 404 411
104. C. Nojgaard, J.S. Johansen, E. Christensen, L.T. Skovgaard, P.A. Price, and U. Becker Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease J Hepatol 39 2003 179 186
105. J.J. Cho, B. Hocher, H. Herbst, J.D. Jia, M. Ruehl, and E.G. Hahn An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis Gastroenterology 118 2000 1169 1178
106. S. Reif, H. Aeed, Y. Shilo, R. Reich, Y. Kloog, and Y.O. Kweon Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid J Hepatol 41 2004 235 241
107. T. Miyahara, L. Schrum, R. Rippe, S. Xiong, H.F. Yee Jr, and K. Motomura Peroxisome proliferator-activated receptors and hepatic stellate cell activation J Biol Chem 275 2000 35715 35722
108. F. Marra, E. Efsen, R.G. Romanelli, A. Caligiuri, S. Pastacaldi, and G. Batignani Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells Gastroenterology 119 2000 466 478
109. K. Hellemans, P. Verbuyst, E. Quartier, F. Schuit, K. Rombouts, and R.A. Chandraratna Differential modulation of rat hepatic stellate phenotype by natural and synthetic retinoids Hepatology 39 2004 97 108
110. J. Cheng, H. Imanishi, W. Liu, A. Iwasaki, N. Ueki, and H. Nakamura Inhibition of the expression of alpha-smooth muscle actin in human hepatic stellate cell line, LI90, by a selective cyclooxygenase 2 inhibitor, NS-398 Biochem Biophys Res Commun 297 2002 1128 1134
111. E. Efsen, A. Bonacchi, S. Pastacaldi, A.J. Valente, U.O. Wenzel, and C. Tosti-Guerra Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells Hepatology 33 2001 713 721
112. J.G. Orr, V. Leel, G.A. Cameron, C.J. Marek, E.L. Haughton, and L.J. Elrick Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells Hepatology 40 2004 232 242
113. W. Yang, H. Chen, and Y. Jiang Inhibitive effect of curcumin and amiloride on the fibrosis of rat hepatic stellate cells induced by oxidative stress Zhong Yao Cai 26 2003 795 798
114. A. Benedetti, A. Di Sario, A. Casini, F. Ridolfi, E. Bendia, and P. Pigini Inhibition of the NA(+)/H(+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study Gastroenterology 120 2001 545 556
115. A. Di Sario, E. Bendia, S. Taffetani, M. Marzioni, C. Candelaresi, and P. Pigini Selective Na+/H+ exchange inhibition by cariporide reduces liver fibrosis in the rat Hepatology 37 2003 256 266
116. S.K. Balk, H.S. Jo, K.T. Suk, J.M. Kim, B.J. Lee, and Y.J. Choi Inhibitory effect of angiotensin II receptor antagonist on the contraction and growth of hepatic stellate cells Korean J Gastroenterol 42 2003 134 141
117. H. Yoshiji, S. Kuriyama, and H. Fukui Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor Tumour Biol 23 2002 348 356
118. H. Okuyama, Y. Shimahara, N. Kawada, S. Seki, D.B. Kristensen, and K. Yoshizato Regulation of cell growth by redox-mediated extracellular proteolysis of platelet-derived growth factor receptor beta J Biol Chem 276 2001 28274 28280
119. H. Iwamoto, H. Sakai, S. Tada, M. Nakamuta, and H. Nawata Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesion J Lab Clin Med 134 1999 83 89
120. H. Iwamoto, H. Sakai, K. Kotoh, M. Nakamuta, and H. Nawata Soluble Arg-Gly-Asp peptides reduce collagen accumulation in cultured rat hepatic stellate cells Dig Dis Sci 44 1999 1038 1045
121. M.C. Gutierrez-Ruiz, L. Bucio, A. Correa, V. Souza, E. Hernandez, and L.E. Gomez-Quiroz Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture Pharmacol Res 44 2001 431 436
122. K.S. Lee, S.J. Lee, H.J. Park, J.P. Chung, K.H. Han, and C.Y. Chon Oxidative stress effect on the activation of hepatic stellate cells Yonsei Med J 42 2001 1 8
123. M. Parola, G. Leonarduzzi, F. Biasi, E. Albano, M.E. Biocca, and G. Poli Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis Hepatology 16 1992 1014 1021
124. A. Pavanato, M.J. Tunon, S. Sanchez-Campos, C.A. Marroni, S. Llesuy, and J. Gonzalez-Gallego Effects of quercetin on liver damage in rats with carbon tetrachloride-induced cirrhosis Dig Dis Sci 48 2003 824 829
125. A. Chen, L. Zhang, J. Xu, and J. Tang The antioxidant (-)-epigallocatechin-3-gallate inhibits activated hepatic stellate cell growth and suppresses acetaldehyde-induced gene expression Biochem J 368 2002 695 704
126. S. Godichaud, S. Krisa, B. Couronne, L. Dubuisson, J.M. Merillon, and A. Desmouliere Deactivation of cultured human liver myofibroblasts by trans-resveratrol, a grapevine-derived polyphenol Hepatology 31 2000 922 931
127. W. Li, C. Wang, and J. Zhang Effects of da ding feng zhu decoction in 30 cases of liver fibrosis J Tradit Chin Med 23 2003 251 254
128. M.P. Germano, V. D'Angelo, R. Sanogo, A. Morabito, S. Pergolizzi, and R. De Pasquale Hepatoprotective activity of Trichilia roka on carbon tetrachloride-induced liver damage in rats J Pharm Pharmacol 53 2001 1569 1574
129. J.D. Jia, M. Bauer, J.J. Cho, M. Ruehl, S. Milani, and G. Boigk Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1 J Hepatol 35 2001 392 398
130. K. Kayano, I. Sakaida, K. Uchida, and K. Okita Inhibitory effects of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells J Hepatol 29 1998 642 649
131. L. Wang, J. Wang, B.E. Wang, P.G. Xiao, and Y.J. Qiao Effects of herbal compound 861 on human hepatic stellate cell proliferation and activation World J Gastroenterol 10 2004 2831 2835
132. C.H. Liu, P. Liu, Y.Y. Hu, L.M. Xu, Y.Z. Tan, and Z.N. Wang Effects of salvianolic acid-A on rat hepatic stellate cell proliferation and collagen production in culture Acta Pharmacol Sin 21 2000 721 726
133. X.L. Zhang, L. Liu, and H.Q. Jiang Salvia miltiorrhiza monomer IH764-3 induces hepatic stellate cell apoptosis via caspase-3 activation World J Gastroenterol 8 2002 515 519
134. G. Ji, Y.Q. Wang, and C.L. Cao Clinical study on treatment of alcoholic liver disease by qinggan huoxue recipe Zhongguo Zhong Xi Yi Jie He Za Zhi 24 2004 13 16
135. Z. Huang, Q. Li, and Z. Wang Observation on dynamic changes of serum procollagen III, hyaluronic acid and laminin in rats with hepatic fibrosis treated with Hujin pill Zhongguo Zhong Xi Yi Jie He Za Zhi 20 2000 447 449
136. L. Li, M. Xu, and Z.L. Liu Effect of dahuang zhechong pill on transforming growth factor-beta 1 in hepatic stellate cells in rats Zhongguo Zhong Xi Yi Jie He Za Zhi 23 2003 763 766
137. Y. Lu, T. Lu, and M. Cheng Changes of collagenase activity in immune hepatic fibrosis following pig's serum injection and therapeutic effect of HanDanGanLe Zhonghua Gan Zang Bing Za Zhi 8 2000 108 109
138. W.S. Zhang, M.L. Cheng, and Y.Y. Lu Effect of HanDanGanLe on the cytokines in fibrotic rats Zhonghua Gan Zang Bing Za Zhi 11 2003 285 287
139. Y. Imanishi, N. Maeda, K. Otogawa, S. Seki, H. Matsui, and N. Kawada Herb medicine Inchin-ko-to (TJ-135) regulates PDGF-BB-dependent signaling pathways of hepatic stellate cells in primary culture and attenuates development of liver fibrosis induced by thioacetamide administration in rats J Hepatol 41 2004 242 250
140. M.L. Cheng, J. Wu, W.S. Zhang, H.Q. Wang, C.X. Li, and N.H. Huang Effect of Maotai liquor on the liver: an experimental study Hepatobiliary Pancreat Dis Int 3 2004 93 98
141. S.W. Woo, J.X. Nan, S.H. Lee, E.J. Park, Y.Z. Zhao, and D.H. Sohn Aloe emodin suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture Pharmacol Toxicol 90 2002 193 198
142. S. Zheng, and A. Chen Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes inhepatic stellate cell in vitro Biochem J Aug 23 2004 [Pt, Epub ahead of print]
143. E.J. Park, G. Ko, J. Kim, and D.H. Sohn Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction Biol Pharm Bull 20 1997 417 420
144. J.Y. Wang, J.S. Guo, H. Li, S.L. Liu, and M.A. Zern Inhibitory effect of glycyrrhizin on NF-kappaB binding activity in CC14- plus ethanol-induced liver cirrhosis in rats Liver 18 1998 180 185
145. P. Muriel, and V. Castro Effects of S-adenosyl-l-methionine and interferon-alpha2b on liver damage induced by bile duct ligation in rats J Appl Toxicol 18 1998 143 147
146. P. Muriel, O.R. Suarez, P. Gonzalez, and L. Zuniga Protective effect of S-adenosyl-l-methionine on liver damage induced by biliary obstruction in rats: a histological, ultrastructural and biochemical approach J Hepatol 21 1994 95 102
147. J. George, D. Roulot, V.E. Koteliansky, and D.M. Bissell In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis Proc Natl Acad Sci USA 96 1999 12719 12724
148. Q.H. Nie, Y.Q. Cheng, Y.M. Xie, Y.X. Zhou, and Y.Z. Cao Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis World J Gastroenterol 7 2001 363 369
149. Z. Qi, N. Atsuchi, A. Ooshima, A. Takeshita, and H. Ueno Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat Proc Natl Acad Sci USA 96 1999 2345 2349
150. E. Borkham-Kamphorst, D. Stoll, A.M. Gressner, and R. Weiskirchen Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis Biochem Biophys Res Commun 321 2004 413 423
151. X. Liu, Z. Zhang, L. Yang, D. Chen, and Y. Wang Inhibition of the activation and collagen production of cultured rat hepatic stellate cells by antisense oligonucleotides against transforming growth factor-beta 1 is enhanced by cationic liposome delivery Hua Xi Yi Ke Da Xue Xue Bao 31 2000 133 135
152. W.B. Liu, C.Q. Yang, W. Jiang, Y.Q. Wang, J.S. Guo, and B.M. He Inhibition on the production of collagen type I, III of activated hepatic stellate cells by antisense TIMP-1 recombinant plasmid World J Gastroenterol 9 2003 316 319
153. L. Beljaars, B. Weert, A. Geerts, D.K. Meijer, and K. Poelstra The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue Biochem Pharmacol 66 2003 1307 1317
154. W. Jiang, C.Q. Yang, W.B. Liu, Y.Q. Wang, B.M. He, and J.Y. Wang Blockage of transforming growth factor beta receptors prevents progression of pig serum-induced rat liver fibrosis World J Gastroenterol 10 2004 1634 1638
155. S. Fiorucci, E. Antonelli, O. Morelli, A. Mencarelli, A. Casini, and T. Mello NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension Proc Natl Acad Sci USA 98 2001 8897 8902
156. P. Failli, R.M.S. DeFranco, A. Caligiuri, A. Gentilini, R.G. Romanelli, and F. Marra Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells Gastroenterology 119 2000 479 492